Insulin Management for Patients with Renal Impairment and Morning Hypoglycemia

Insulin Selection and Dosing Considerations

Long-acting insulin analogs, such as degludec, have demonstrated significantly lower rates of hypoglycemia compared to NPH insulin, with degludec showing the most favorable profile, according to the American Diabetes Association 1
For patients with renal impairment, lower insulin doses are generally required due to decreased insulin clearance, increasing the risk of hypoglycemia, as recommended by the American Diabetes Association 2
Start with a reduced insulin dose in patients with renal impairment, approximately 0.1-0.2 units/kg/day for basal insulin, as suggested by the American Diabetes Association 5

If a patient is currently on NPH insulin and experiencing morning hypoglycemia, consider switching to a long-acting basal analog, such as degludec or glargine, as recommended by the American Diabetes Association 3
For patients with nocturnal or morning hypoglycemia, insulin degludec provides a reduced risk of nocturnal hypoglycemia compared to NPH insulin, according to the American Diabetes Association 4
For hospitalized patients with renal impairment, consider a basal-plus approach rather than basal-bolus to minimize hypoglycemia risk, as suggested by the Endocrine Society 8
For patients with type 1 diabetes and renal impairment, a basal-bolus regimen is still necessary, but with reduced doses of both basal and prandial insulin, as recommended by the American Diabetes Association 7